268600 — Cellivery Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual cashflow statement for Cellivery Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-19,650	-17,248	-28,069	-75,159	-34,036
Depreciation
Amortisation
Non-Cash Items	7,572	2,926	7,583	14,126	13,207
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-501	-2,813	-3,719	-544	7,088
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-11,581	-16,097	-22,744	-56,381	-8,791
Capital Expenditures	-630	-1,208	-4,590	-17,649	-64.5
Purchase of Fixed Assets
Other Investing Cash Flow Items	9,496	-697	-3,959	13,134	3,951
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	8,867	-1,905	-8,549	-4,514	3,887
Financing Cash Flow Items	-0.438	-516	-1,486	-53.9	-2.98
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	2,976	45,442	71,941	6,117	-8,216
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	262	27,433	40,647	-54,748	-13,119